Day: January 13, 2023

Posted on

Jazz conducts successful trial of Pakistan’s first 1.2Tbps transport network with Huawei

KARACHI: Jazz, Pakistan’s leading digital operator and part of VEON Group, has successfully conducted trial of Pakistan’s first 1.2Tbps (1200Gbps) transport network. This technology increases the optical fiber capacities by 50% from its existing 800Gbps over a single wavelength.

The trial was conducted in a live network in collaboration with Huawei, during which Jazz commercial network was upgraded to 1.2Tbps per wavelength. Jazz is the first operator to introduce next-generation transport network solution on its network. With over 15,000 operational cell sites this new technology will help Jazz meet its customers’ growing needs of data services.

Commenting on this industry-first development, Jazz’s Chief Technology Officer, Khalid Shehzad said, “Our customers are increasingly using high-bandwidth applications which has led to an amplified demand for faster data. The 1.2T technology allows us the freedom to provide more data at greater speeds in an efficient manner enabling our customers to use enhanced services on their 4G devices.”

The demand for broadband speed and volume grows exponentially with a rise in low-latency services like virtual meetings, online gaming, video streaming, etc. Recently, Jazz also successfully launched 400G technology on its long-haul optical transport network and 800G on its metro and datacenter networks.

Posted on

Pakistan committed to further strengthen tie with UAE: PM

ISLAMABAD: Prime Minister Shehbaz Sharif has reaffirmed Pakistan’s commitment to further strengthen existing bilateral engagements with the United Arab Emirates (UAE) at all levels and fields including trade, investment, energy, culture and tourism.

He was talking to Minister for Tolerance of United Arab Emirates Sheikh Nahyan bin Mubarik who called on him in Abu Dhabi on Friday. The Prime Minister invited the UAE to make more investments in energy, aviation and tourism sectors and appreciated the efforts of the brotherly country to promote peace and stability in the region. The UAE’s Minister praised the dedication and hard work of the Pakistani community which is significantly contributing towards the development of the UAE.

Posted on

Board of directors meeting of Unity Foods Limited

Karachi, Unity Foods Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on January 20, 2023 at Karachi. The agenda of the meeting will to consider the Annual Accounts for the period ended June 30, 2022.

Further, the company has declared the closed period from January 13, 2023 to January 20, 2023.

Unity Foods Limited was incorporated in Pakistan in 1991 as a Private Limited Company and subsequently converted into a Public Limited Company on June 16, 1991. The principal business activity of the Company has been changed from yarn manufacturing to edible oil extraction, refining and related businesses.

The total numbers of shares are 994,050,000. The earnings per share is 0.39 in 2020 which was 1.03 in 2019. The profit after Taxation is 209,629,000 in 2020 which was 255,075,000 in 2019.

Posted on

Board Meeting other than Financial Result of Nishat Mills Limited

Karachi, Nishat Mills Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on January 20, 2023 at Lahore to consider the matters other than financial results.

Further, the company has declared the closed period from January 13, 2023 to January 20, 2023.

Nishat Mills Limited is the flagship company of Nishat Group. It is a public limited company incorporated in Pakistan in 1951 under the Companies Ordinance, 1984. The production facilities of the company comprises of spinning, weaving, processing, stitching and power generation. The shares of the company are quoted on the Karachi, Lahore and Islamabad Stock exchanges of Pakistan. The registered office of the company is located at Lahore.

The company is engaged in the business of textile manufacturing and of spinning, combing, weaving, bleaching, dyeing, printing, stitching, apparel, buying, selling and otherwise dealing in yarn, linen, cloth and other goods and fabrics made from raw cotton, synthetic fibre and cloth and to generate, accumulate, distribute, supply and sell electricity. It has 198,120 spindles, 655 Toyota air jet looms, textile dyeing and processing units, 2 stitching units for home textile, one stitching unit for garments and Power Generation facilities with a capacity of 89 MW.

The subsidiary companies of Nishat Mills Limited include Nishat Power Limited, Nishat Linen Private Limited, Nishat Hospitality Private Limited, Nishat USA, Inc. and Nishat Linen Trading L.L.C.

The symbol “NML” is being used by the stock exchanges for the shares of Nishat Mills Limited.

Posted on

Board Meeting of Data Textiles Limited

Karachi, Data Textiles Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on January 20, 2023 at Lahore to consider the Annual Accounts for the period ended June 30, 2022 for declaration of any entitlement.

Data Textiles started commercial operations in October 1991.The main activity of the company is manufacturing and sale of yarn. The total numbers of shares are 9,909,600. The Earnings per share is (0.03) in 2020 which was (0.03) in 2019. The Company had a loss of Rs. 2,541,000 in 2020 which was 2,530,000 in 2019.

Posted on

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Avaya Holdings Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AVYA, AVYAW

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Avaya Holdings Corp. (NYSE: AVYA) (OTC: AVYAW) between November 22, 2021 and November 29, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023.

SO WHAT: If you purchased Avaya securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s internal control over financial reporting (“ICFR”) was deficient in several areas; (2) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (3) the Company’s deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8729172

Posted on

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b

GlobeNewswire Distribution ID 8728283